Share This Post

Focus in RCC shifts to new frontline strategies

From OncLive

Three recent drug approvals have shifted the landscape in the second-line setting for renal cell carcinoma (RCC), and researchers are now setting their sights on transforming upfront care, according to Chung-Han (Joe) Lee, MD

See more at: http://www.onclive.com/web-exclusives/after-secondline-rcc-approvals-focus-shifts-to-frontline#sthash.4zOJZVsu.dpuf

 

Share This Post

Dena Battle is the President of KCCure. She also serves on the Advisory Board for the Johns Hopkins Sidney Kimmel Cancer Center and as a member of the Patient and Family Advisory Council.

Lost Password

Register

Subscribe for updates!